Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
October 1, 2023
Birtamimab is an investigational humanized monoclonal antibody designed to neutralize toxic LC aggregates and deplete insoluble organ-deposited amyloid via macrophage-induced phagocytosis. Per this study, it was effective in Mayo stage 4 amyloidosis.
It is a rare disease, but at least now it has a possible option.
